CATALYST BIOSCIENCES INC (CBIO) 0.295 -0.01 (-2.99%)
0.295 -0.01 (-2.99%)
US14888D2080 - Common Stock - After market: 0.3 +0.01 (+1.69%)
Fundamental Rating
We assign a fundamental rating of 5 out of 10 to CBIO. CBIO was compared to 639 industry peers in the Biotechnology industry. CBIO has a great profitability rating, but there are some minor concerns on its financial health. CBIO is quite expensive at the moment. It does show a decent growth rate.
Profitability
Profitability Rating
CBIO has a Return On Assets of 38.31%. This is amongst the best returns in the industry. The industry average is 12.39%. CBIO outperforms 92% of its industry peers.
CBIO's Return On Equity of 40.45% is amongst the best of the industry. CBIO does better than the industry average Return On Equity of 23.70%.
CBIO's Profit Margin of 367.44% is amongst the best returns of the industry. CBIO outperforms 95% of its industry peers. The industry average Profit Margin is 27.64%.
CBIO has a Piotroski-F score of 5.00. This indicates an average health and profitability for CBIO.
VS Industry
ROA (38.31%) VS Industry: 92% outperformed.
0.11
52.28
ROE (40.45%) VS Industry: 65% outperformed.
0.21
217.75
Profit Margin (367.44%) VS Industry: 95% outperformed.
0.84
1,971.30
Valuation
Valuation Rating
When comparing the current price to the book value of CBIO, it is valued rather cheaply. It is trading at 0.32 times its book value.
When comparing the price book ratio of CBIO to the average industry price book ratio of 1.87, CBIO is valued rather cheaply. CBIO is also cheaper than 95% of the companies listed in the same industry.
CBIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CBIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
VS Industry
Price/Book (0.32) VS Industry: 95% outperformed.
464.05
0.07
Growth
Growth Rating
The Earnings Per Share has grown by an impressive 53.40% over the past year.
The Earnings Per Share is expected to grow by 23.79% on average over the next 5 years. This is a very strong growth
CBIO shows a strong growth in Revenue. Measured over the last 5 years, the Revenue has been growing by 78.94% yearly.
Looking at the last year, CBIO shows a very negative growth in Revenue. The Revenue has decreased by -53.34% in the last year.
CBIO is expected to show a very negative growth in Revenue. In the coming 5 years, the Revenue will decrease by -14.87% yearly.
The Revenue growth is decreasing: in the next 5 years the growth will be less than in the last years.
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | N/A | N/A | 53.4% | 131.99% | 36.82% | 23.79% | N/A |
| Revenue | 78.94% | 801.97% | -53.34% | -84.43% | -41.42% | -25.99% | -14.87% |
Health
Health Rating
A Current Ratio of 18.40 indicates that CBIO has no problem at all paying its short term obligations.
The Current Ratio of CBIO is much better than the industry average of 6.21. CBIO has a better rating than 90% of its industry peers.
CBIO has a Quick Ratio of 18.40. This indicates that CBIO is financially healthy and has no problem in meeting its short term obligations.
CBIO is one of the better placed companies in its industry to meet its short term obligations. Its Current Ratio is much better than the industry average of 6.11. CBIO has a better rating than 90% of its industry peers.
The Debt to Equity ratio of CBIO is in line with the industry averages.
CBIO has a Piotroski-F score of 5.00. This indicates an average health and profitability for CBIO.
Based on the Altman-Z score of -16.90, we must say that CBIO is in the distress zone and has some risk of bankruptcy.
Compared to an average industry Altman-Z score of -0.13, CBIO is in worse financial state than most of its industry peers. 91% of its industry peers have a better Altman-Z score.
VS Industry
Debt/Equity (0) VS Industry: 42% outperformed.
15.37
0.00
Quick Ratio (18.4) VS Industry: 90% outperformed.
0.04
84.53
Current Ratio (18.4) VS Industry: 90% outperformed.
0.08
85.09
Altman-Z (-16.9) VS Industry: 9% outperformed.
-94.22
622.88
Dividend
Dividend Rating
No dividends for CBIO!.
CATALYST BIOSCIENCES INC0.295
NASDAQ:CBIO (1/27/2023, 7:00:02 PM)-0.01 (-2.99%)
| GICS Sector | Health Care | ||
| GICS IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences | ||
| GICS Industry | Biotechnology | ||
| Earnings (Last) | 11-14 2022-11-14/dmh | Earnings (Next) | 03-29 2023-03-29 |
| Inst Owners | 24.56% | Inst Owner Change | -0.01% |
| Ins Owners | 17.49% | Ins Owner Change | 0.18% |
| Market Cap | 9.29M | Analysts | 77.78 |
| Price Target | 16.32 (5432.2%) | ||
| Dividend Yield | N/A | Dividend Growth | N/A |
| DP | N/A | Ex-Date | 01-13 2023-01-13 (0.24) |
| EPS beat(2) | 1 | Avg EPS beat(2) | -14.45% |
| Min EPS beat(2) | -56.86% | Max EPS beat(2) | 27.97% |
| EPS beat(4) | 1 | Avg EPS beat(4) | -9.35% |
| Min EPS beat(4) | -56.86% | Max EPS beat(4) | 27.97% |
| Revenue beat(2) | N/A | Avg Revenue beat(2) | N/A |
| Min Revenue beat(2) | N/A | Max Revenue beat(2) | N/A |
| Revenue beat(4) | N/A | Avg Revenue beat(4) | N/A |
| Min Revenue beat(4) | N/A | Max Revenue beat(4) | N/A |
| PT rev (1m) | 0% | EPS NQ rev (1m) | 0% |
| EPS NY rev (1m) | 0% | Revenue NQ rev (1m) | N/A |
| Revenue NY rev (1m) | 0% | ||
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 2.87 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.32 | ||
| P/tB | 0.32 | ||
| EV/EBITDA | N/A |
| EPS(TTM) | -1.44 | EY | N/A |
| EPS(NY) | -0.37 | Fwd EY | N/A |
| FCF(TTM) | -1.57 | FCFY | N/A |
| OCF(TTM) | -1.57 | OCFY | N/A |
| SpS | 0.1 | BVpS | 0.93 |
| TBVpS | 0.93 | PEG (NY) | N/A |
| PEG (5Y) | N/A | ||
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 38.31% | ||
| ROE | 40.45% | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM | 367.44% | ||
| GM | N/A |
| ROICexgc(3y) | N/A | ROICexcg growth 3Y | N/A |
| ROICexcg growth 5Y | N/A | ROICexc(3y) | N/A |
| ROICexc growth 3Y | N/A | ROICexc growth 5Y | N/A |
| OM growth 3Y | N/A | OM growth 5Y | N/A |
| PM growth 3Y | N/A | PM growth 5Y | N/A |
| GM growth 3Y | N/A | GM growth 5Y | N/A |
| F-Score | 5 | Asset Turnover | 0.1 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 0% | ||
| Profit Quality | N/A | ||
| Current Ratio | 18.4 | ||
| Quick Ratio | 18.4 | ||
| Altman-Z | -16.9 |
| F-Score | 5 | WACC | 8.99% |
| ROIC/WACC | N/A | Cap/Depr(3y) | 229.77% |
| Cap/Depr(5y) | 217.86% | Profit Quality(3y) | N/A |
| Profit Quality(5y) | N/A | ||
| EPS 1Y | 53.4% | EPS 3Y | N/A |
| EPS 5Y | N/A | EPS growth Q2Q | 80% |
| EPS Next Y | 131.99% | EPS Next 2Y | 36.82% |
| EPS Next 3Y | 23.79% | EPS Next 5Y | N/A |
| Revenue growth 1Y | -53.34% | Revenue growth 3Y | 801.97% |
| Revenue growth 5Y | 78.94% | Revenue growth Q2Q | -100% |
| Revenue Next Year | -84.43% | Revenue Next 2Y | -41.42% |
| Revenue Next 3Y | -25.99% | Revenue Next 5Y | -14.87% |
| EBIT growth 1Y | 48.05% | EBIT growth 3Y | N/A |
| EBIT growth 5Y | N/A | EBIT Next Year | N/A |
| EBIT Next 3Y | N/A | EBIT Next 5Y | N/A |
| FCF growth 1Y | -19.65% | FCF growth 3Y | N/A |
| FCF growth 5Y | N/A | OCF growth 1Y | -20.24% |
| OCF growth 3Y | N/A | OCF growth 5Y | N/A |
Fundamental Stock Screener Links
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA